Call Us - We're Easy to Talk To (214) 999-9999

New Jersey Vioxx Jury Awards Punitive Damages

As reported by Reuters, a jury on Tuesday awarded $9 million in punitive damages to a New Jersey man who blamed Merck & Co. Inc.’s Vioxx for his heart attack. Excerpts:

The punitive damages come on top of $4.5 million in compensatory damages the jury awarded 77-year-old John McDarby last week after they found Vioxx was a significant contributing factor to his heart attack and that Merck failed to adequately warn of the drug’s risks.

Merck, which pulled the $2.5 billion-a-year drug off the market in September 2004, said it would appeal the verdicts.

For the punitive damages, the jury of six women and two men in New Jersey Superior Court determined that Merck withheld material information on Vioxx from the U.S. Food and Drug Administration and the company’s actions were deliberately meant to harm.

Merck expressed disappointment over the jury’s decision but gave no indication that it was willing to consider settling some of the cases it is facing.

As part of its deliberations, the jury considered whether Merck intentionally withheld from regulators an analysis of several clinical trials done by a company statistician in 2000 that showed a higher incidence of heart attacks among patients taking Vioxx than those taking other drugs.

Bob Kraft

I am a Dallas, Texas lawyer who has had the privilege of helping thousands of clients since 1971 in the areas of Personal Injury law and Social Security Disability.

About This Blog

The title of this blog reflects my attitude toward those government agencies and insurance companies that routinely mistreat injured or disabled people. As a Dallas, Texas lawyer, I've spent more than 45 years trying to help those poor folk, and I have been frustrated daily by the actions of the people on the other side of their claims. (Sorry if I offended you...)

If you find this type of information interesting or helpful, please visit my law firm's main website at KraftLaw.com. You will find many more articles and links. Thank you for your time.

Find us on your preferred network